176 related articles for article (PubMed ID: 36317935)
1. Evaluation of emerging NASH therapies: the impact of treatment efficacy profiles on long-term health outcomes.
Herring WL; Gould IG; Wittrup-Jensen V; Ertle J; Kuti E; Wolowacz S
J Comp Eff Res; 2022 Dec; 11(18):1349-1363. PubMed ID: 36317935
[TBL] [Abstract][Full Text] [Related]
2. Clinical characteristics and management of patients with nonalcoholic steatohepatitis in a real-world setting: analysis of the Ipsos NASH therapy monitor database.
Shelley K; Articolo A; Luthra R; Charlton M
BMC Gastroenterol; 2023 May; 23(1):160. PubMed ID: 37208593
[TBL] [Abstract][Full Text] [Related]
3. The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis.
Younossi ZM; Anstee QM; Wai-Sun Wong V; Trauner M; Lawitz EJ; Harrison SA; Camargo M; Kersey K; Subramanian GM; Myers RP; Stepanova M
Gastroenterology; 2021 Apr; 160(5):1608-1619.e13. PubMed ID: 33307033
[TBL] [Abstract][Full Text] [Related]
4. The Potential Role of Fatigue in Identifying Patients With NASH and Advanced Fibrosis Who Experience Disease Progression.
Younossi ZM; Stepanova M; Myers RP; Younossi I; Henry L
Clin Gastroenterol Hepatol; 2023 Apr; 21(4):970-977.e1. PubMed ID: 35533993
[TBL] [Abstract][Full Text] [Related]
5. Analysis of a Simulation Model to Estimate Long-term Outcomes in Patients with Nonalcoholic Fatty Liver Disease.
Chhatwal J; Dalgic OO; Chen W; Samur S; Bethea ED; Xiao J; Hur C; Corey KE; Loomba R
JAMA Netw Open; 2022 Sep; 5(9):e2230426. PubMed ID: 36098969
[TBL] [Abstract][Full Text] [Related]
6. Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis.
Musso G; Cassader M; Paschetta E; Gambino R
JAMA Intern Med; 2017 May; 177(5):633-640. PubMed ID: 28241279
[TBL] [Abstract][Full Text] [Related]
7. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials.
Harrison SA; Wong VW; Okanoue T; Bzowej N; Vuppalanchi R; Younes Z; Kohli A; Sarin S; Caldwell SH; Alkhouri N; Shiffman ML; Camargo M; Li G; Kersey K; Jia C; Zhu Y; Djedjos CS; Subramanian GM; Myers RP; Gunn N; Sheikh A; Anstee QM; Romero-Gomez M; Trauner M; Goodman Z; Lawitz EJ; Younossi Z; ;
J Hepatol; 2020 Jul; 73(1):26-39. PubMed ID: 32147362
[TBL] [Abstract][Full Text] [Related]
8. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.
Harrison SA; Bedossa P; Guy CD; Schattenberg JM; Loomba R; Taub R; Labriola D; Moussa SE; Neff GW; Rinella ME; Anstee QM; Abdelmalek MF; Younossi Z; Baum SJ; Francque S; Charlton MR; Newsome PN; Lanthier N; Schiefke I; Mangia A; Pericàs JM; Patil R; Sanyal AJ; Noureddin M; Bansal MB; Alkhouri N; Castera L; Rudraraju M; Ratziu V;
N Engl J Med; 2024 Feb; 390(6):497-509. PubMed ID: 38324483
[TBL] [Abstract][Full Text] [Related]
9. A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis.
Harrison SA; Goodman Z; Jabbar A; Vemulapalli R; Younes ZH; Freilich B; Sheikh MY; Schattenberg JM; Kayali Z; Zivony A; Sheikh A; Garcia-Samaniego J; Satapathy SK; Therapondos G; Mena E; Schuppan D; Robinson J; Chan JL; Hagerty DT; Sanyal AJ
J Hepatol; 2020 May; 72(5):816-827. PubMed ID: 31887369
[TBL] [Abstract][Full Text] [Related]
10. Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design.
Anstee QM; Neuschwander-Tetri BA; Wong VW; Abdelmalek MF; Younossi ZM; Yuan J; Pecoraro ML; Seyedkazemi S; Fischer L; Bedossa P; Goodman Z; Alkhouri N; Tacke F; Sanyal A
Contemp Clin Trials; 2020 Feb; 89():105922. PubMed ID: 31881392
[TBL] [Abstract][Full Text] [Related]
11. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.
Younossi ZM; Ratziu V; Loomba R; Rinella M; Anstee QM; Goodman Z; Bedossa P; Geier A; Beckebaum S; Newsome PN; Sheridan D; Sheikh MY; Trotter J; Knapple W; Lawitz E; Abdelmalek MF; Kowdley KV; Montano-Loza AJ; Boursier J; Mathurin P; Bugianesi E; Mazzella G; Olveira A; Cortez-Pinto H; Graupera I; Orr D; Gluud LL; Dufour JF; Shapiro D; Campagna J; Zaru L; MacConell L; Shringarpure R; Harrison S; Sanyal AJ;
Lancet; 2019 Dec; 394(10215):2184-2196. PubMed ID: 31813633
[TBL] [Abstract][Full Text] [Related]
12. Hypothetical treatment of patients with non-alcoholic steatohepatitis: Potential impact on important clinical outcomes.
Younossi ZM; Tampi RP; Nader F; Younossi IM; Cable R; Srishord M; Racila A
Liver Int; 2020 Feb; 40(2):308-318. PubMed ID: 31705834
[TBL] [Abstract][Full Text] [Related]
13. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
Ratziu V; Harrison SA; Francque S; Bedossa P; Lehert P; Serfaty L; Romero-Gomez M; Boursier J; Abdelmalek M; Caldwell S; Drenth J; Anstee QM; Hum D; Hanf R; Roudot A; Megnien S; Staels B; Sanyal A;
Gastroenterology; 2016 May; 150(5):1147-1159.e5. PubMed ID: 26874076
[TBL] [Abstract][Full Text] [Related]
14. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
Newsome PN; Buchholtz K; Cusi K; Linder M; Okanoue T; Ratziu V; Sanyal AJ; Sejling AS; Harrison SA;
N Engl J Med; 2021 Mar; 384(12):1113-1124. PubMed ID: 33185364
[TBL] [Abstract][Full Text] [Related]
15. Increasing metabolic co-morbidities are associated with higher risk of advanced fibrosis in nonalcoholic steatohepatitis.
Wong RJ; Tran T; Kaufman H; Niles J; Gish R
PLoS One; 2019; 14(8):e0220612. PubMed ID: 31369606
[TBL] [Abstract][Full Text] [Related]
16. The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials.
Sanyal AJ; Harrison SA; Ratziu V; Abdelmalek MF; Diehl AM; Caldwell S; Shiffman ML; Aguilar Schall R; Jia C; McColgan B; Djedjos CS; McHutchison JG; Subramanian GM; Myers RP; Younossi Z; Muir AJ; Afdhal NH; Bosch J; Goodman Z
Hepatology; 2019 Dec; 70(6):1913-1927. PubMed ID: 30993748
[TBL] [Abstract][Full Text] [Related]
17. Biopsy rate and nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD).
Gerhardt F; Petroff D; Blank V; Böhlig A; van Bömmel F; Wittekind C; Berg T; Karlas T; Wiegand J
Scand J Gastroenterol; 2020 Jun; 55(6):706-711. PubMed ID: 32476514
[No Abstract] [Full Text] [Related]
18. Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects.
Ampuero J; Aller R; Gallego-Durán R; Crespo J; Abad J; González-Rodríguez Á; Gómez-Camarero J; Caballería J; Lo Iacono O; Ibañez L; García-Samaniego J; Martín-Mateos R; Francés R; Fernández-Rodríguez C; Diago M; Soriano G; Andrade RJ; Latorre R; Jorquera F; Morillas RM; Escudero D; Estévez P; Hernández-Guerra M; Augustín S; Pareja-Megia MJ; Banales JM; Aspichueta P; Benlloch S; Rosales JM; Salmerón J; Turnes J; Romero-Gómez M;
Liver Int; 2021 Sep; 41(9):2076-2086. PubMed ID: 33896100
[TBL] [Abstract][Full Text] [Related]
19. The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis.
Abdelmalek MF; Charles ED; Sanyal AJ; Harrison SA; Neuschwander-Tetri BA; Goodman Z; Ehman RA; Karsdal M; Nakajima A; Du S; Tirucherai GS; Klinger GH; Mora J; Yamaguchi M; Shevell DE; Loomba R
Contemp Clin Trials; 2021 May; 104():106335. PubMed ID: 33657443
[TBL] [Abstract][Full Text] [Related]
20. Impact of laparoscopic sleeve gastrectomy on fibrosis stage in patients with child-A NASH-related cirrhosis.
Salman MA; Mikhail HMS; Nafea MA; Sultan AAEA; Elshafey HE; Tourky M; Awad A; Abouelregal TE; Ahmed RA; Ashoush O; AbdelAal AA; Shaaban HE; Atallah M; Yousef M; Salman AA
Surg Endosc; 2021 Mar; 35(3):1269-1277. PubMed ID: 32152677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
